Home » Newsletters » BioWorld Science

BioWorld Science

April 1, 2010

View Archived Issues

Greater blood pressure reduction seen with LCZ-696 than with valsartan in hypertension

Pfizer describes identification of selective 5-HT6 receptor antagonist WAY-262531

Preclinical safety of oseltamivir supports clinical development in infants

Studies describe pharmacokinetics, interactions with renin inhibitor ACT-178882/MK-1597

GLY-230 may ameliorate renal disease in patients with diabetes

Discovery of HCV protease inhibitor BMS-650032 described

Targacept presents novel nicotinic acetylcholine alpha4beta2 receptor ligands

UHN claims new triazolium and imidazolium salts for treatment of parasitic infections

Repligen discovers novel HDAC3 inhibitors

Emory University claims new noscapine analogues for cancer therapy

Addex and Ortho-McNeil-Janssen claim positive allosteric mGlu2 modulators

Patient enrollment initiated in phase II study of Reolysin for SCC lung cancer

Emory University and Zirus enter a collaboration and research agreement to create new antivirals

SciClone reports topline phase II data on SCV-07 for prevention of oral mucositis

FDA issues complete response letter on AstraZeneca and Abbott's Certriad NDA for mixed dyslipidemia

FDA approves Asclera for treatment of small varicose veins

Eisai submits anticancer agent eribulin for approval in Japan, U.S. and Europe

Banyu submits V-260 rotavirus vaccine for approval in Japan

BioDiem provides update on pandemic influenza vaccine program

NexMed files IND with FDA for phase II trial of PrevOnco in hepatocellular carcinoma

Action Pharma completes dosing in phase II AP-214 trial

FDA accepts voclosporin NDA for priority review

YM BioSciences expands ongoing phase I/II CYT-387 study in myelofibrosis

Titan begins phase III study of Probuphine in opioid addiction

PolyMedix completes phase Ib trial of novel antibiotic PMX-30063

Critical Outcome Technologies reports preclinical data on oral COTI-2 in TNBC model

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Aug. 3, 2026.
Tuojie Biotech (Shanghai) synthesizes new SARM1 inhibitors
BioWorld Science
Tuojie Biotech (Shanghai) Co. Ltd. has prepared and tested NAD(+) hydrolase SARM1 (SAMD2; MyD88-5) inhibitors found to be potentially useful for the treatment of...
Death in Chinese gene-editing trial exposes ethical fault lines
BioWorld
The death of a 6-year-old girl after receiving an experimental brain-directed gene-editing therapy at the Xinhua Hospital in Shanghai has reopened debate over how...
Seed funding at Adjuvia to treat mitochondrial dysfunction
BioWorld Science
Adjuvia Therapeutics Inc. has closed a $8 million series seed financing round to advance its work developing therapeutics to treat mitochondrial dysfunction and...
Replimune’s RP-1 for melanoma wins over FDA adcom
BioWorld
Following two complete response letters in the past year, Replimune Group Inc.’s RP-1 (suvolimogene oderparepvec) for unresectable metastatic cutaneous melanoma...